Paul Hastings has been named CEO of South San Francisco, CA-based Nkarta Therapeutics. Hastings most recently worked for Redwood City, CA, cancer drug developer OncoMed Pharmaceuticals (NASDAQ: [[ticker:OMED]]), where he was chairman and CEO. Hastings resigned from OncoMed on Jan. 1. Nkarta is developing cancer treatments based on natural killer (NK) immune cells.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
